Posts by Nicholas Alan Clayton

Latest

Morning SPAC News Roundup: November 13, 2026

SPACs have been relatively light on jumpy low float trading situations of late, but one new one may have just been created. Mountain Crest V (OTC:MCAG) held not one, but two votes this week to complete its business combination with VIANIQ as well as extend its transaction deadline to May 2027. More

Nicholas Alan Clayton·Nov 13

Top 3 SPAC Targets – Pharma Manufacturers

As discussed in the last iteration of this column focused on late-stage biotech firms, SPACs have increasingly turned to the drug development sector as a safe space on the board while various types of volatility have cropped up in the fourth quarter of 2026. More

Nicholas Alan Clayton·Nov 12

Morning SPAC News Roundup: November 12, 2026

There are still expected to be new results from SPAC shareholder votes through the rest of this week, but there has been a relative slow-down in other SPAC business after a fast start to November. More

Nicholas Alan Clayton·Nov 12

Morning SPAC News Roundup: November 11, 2026

Futures are currently green after a tumble in reaction to yesterday's CPI inflation numbers that came in slightly hotter than expected. Although this shows that interest rate uncertainty is here to stay for the remainder of the year at least, some SPAC favorite sectors have also seen bounces in the back-and-forth. More

Nicholas Alan Clayton·Nov 11

New SPACs: A Paradise III (APCD.U), ZA I (ZACAU), Research Alliance V (RACV) File for IPOs

A Paradise III Acquisition Corp. A Paradise III (NYSE:APCD.U) has filed for a $100 million IPO to potentially line up a second vehicle for a generalist search. The timing of this filing suggests that this serial sponsor wants to increase the pace of its dealmaking considering that it has A Paradise II (NYSE:APBD. More

Nicholas Alan Clayton·Nov 10

Morning SPAC News Roundup: November 10, 2026

A reading of fresh CPI inflation figures is on the docket followed by a full day of comments by Fed officials. Futures are hopeful on the Dow side for these events, but the Nasdaq has continued to sag as it is down about -9. More

Nicholas Alan Clayton·Nov 10

Globa Terra (GTERA) to Combine with Nature’s Ledger in $324M Deal

Globa Terra (NASDAQ:GTERA) has entered into a definitive agreement to combine with sustainability firm Nature’s Ledger at a $323.8 million pre-money equity value. Nature's Ledger places real world ecological assets on the blockchain to allow investors to trade carbon credits based on their preservation or improvement. More

Nicholas Alan Clayton·Nov 9

Morning SPAC News Roundup: November 9, 2026

Futures are green heading into the first week following the US' midterm elections upheaval. This week is set to host six shareholder votes including a vote to complete a business combination by Mountain Crest V (OTC:MCAG). More

Nicholas Alan Clayton·Nov 9

New SPACs: Churchill Capital XIV (CXIVU), Kartoon Studios (KACQ.U) File for IPOs

Churchill Capital Corp. XIV Churchill XIV has filed for a $300 million SPAC that would give the high-profile team a third vehicle out searching for a deal. The new SPAC is offering investors 1/10 warrants in its units, which is the same structure the team has gone with for the last three SPACs it has filed and IPO'd over the past year. More

Nicholas Alan Clayton·Nov 6

Armada III (AACI) to Combine with Brains Bioceutical in $892M Deal

Armada III (NASDAQ:AACI) has entered into a definitive agreement to combine with drug developer Brains Bioceutical at a pro forma enterprise value of $891.8 million. Brains Bioceutical has built out the manufacturing base to provide medical-grade cannabinoid ingredients to the biotech and consumer industries while pursuing its own potential drug candidates. More

Nicholas Alan Clayton·Nov 6